10-Q: Phio Pharmaceuticals Reports Q1 2024 Results, Focuses on Clinical Development

Phio Pharmaceuticals reported a net loss of $2.154 million for the first quarter of 2024, as it continues to advance its clinical programs and streamline operations.

Summary

• Phio Pharmaceuticals reported a net loss of $2.154 million for the three months ended March 31, 2024, compared to a net loss of $3.602 million for the same period in 2023.
• The company's operating expenses decreased to $2.209 million in Q1 2024 from $3.602 million in Q1 2023, driven by cost rationalization efforts.
• Research and development expenses decreased to $1.148 million from $2.134 million year-over-year, reflecting a shift from research to product development.
• General and administrative expenses also decreased to $1.061 million from $1.468 million year-over-year.
• As of March 31, 2024, Phio had $6.475 million in cash and cash equivalents, down from $8.490 million at the end of 2023.
• The company is currently conducting a Phase 1b clinical trial for its lead product candidate, PH-762, for the treatment of skin cancers.
• Phio terminated its clinical co-development agreement with AgonOx on May 8, 2024, due to enrollment delays in the Phase 1 clinical trial.
• The company expects to complete enrollment in the PH-762 Phase 1b trial in the second quarter of 2025.

Sentiment

Score: 4

Explanation: The document shows some positive signs of cost reduction and clinical trial progress, but the company's financial situation and going concern warning are significant concerns. The termination of the AgonOx collaboration and the Nasdaq listing compliance issues further dampen the sentiment.

Positives

• The company significantly reduced its net loss and operating expenses compared to the same period last year.
• Research and development expenses were reduced due to a shift in focus from research to product development.
• The company has initiated a Phase 1b clinical trial for PH-762, with the first two patients completing treatment without adverse events.
• The company has taken steps to reduce costs by transitioning to a primarily remote business model and reducing headcount by 36%.

Negatives

• The company continues to experience net losses and negative cash flows from operations.
• The company's cash reserves have decreased from $8.490 million at the end of 2023 to $6.475 million as of March 31, 2024.
• The company terminated its clinical co-development agreement with AgonOx due to enrollment delays.
• The company has a going concern warning due to limited cash resources and recurring losses.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• There is no guarantee that the company will be able to raise additional capital through equity or debt offerings.
• The company is subject to the risk of not maintaining compliance with Nasdaq listing requirements.
• The company's clinical trials may not be successful, and its product candidates may not receive regulatory approval.
• The company may face challenges in commercializing its product candidates if approved.

Future Outlook

The company expects to complete enrollment in the PH-762 Phase 1b clinical trial in the second quarter of 2025 and is focused on advancing its clinical programs. The company's future is dependent on securing additional funding.

Management Comments

• The company implemented a cost rationalization program in 2023, driven by its transition from a research company to a product development company.
• The company believes that direct-to-tumor administration of PH-762 resulted in activity against distant untreated tumors, indicative of a systemic anti-tumor response.
• The company is actively monitoring its stockholders equity and will consider any and all options available to us to maintain compliance with Nasdaq Listing Rule 5550(b)(1).

Industry Context

Phio's focus on immuno-oncology and RNA silencing technology aligns with current trends in cancer therapeutics. The company's approach of directly targeting proteins that inhibit the immune system is a common strategy in the field. The termination of the AgonOx collaboration highlights the challenges in developing combination therapies and the need for efficient clinical trial execution.

Comparison to Industry Standards

• Phio's cash burn rate is typical for a clinical-stage biotech company, but the company's cash runway is limited, requiring additional funding.
• The company's focus on a Phase 1b trial is consistent with the development pathway for early-stage therapeutics.
• The termination of the AgonOx collaboration is not uncommon in the biotech industry, where partnerships can be terminated due to various factors, including trial delays or strategic shifts.
• Compared to companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, which are also focused on RNAi therapeutics, Phio is at an earlier stage of development and has a smaller market capitalization.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital.
• Employees may be affected by potential further cost-cutting measures.
• Customers and partners may be concerned about the company's financial stability.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company will continue to enroll patients in the Phase 1b clinical trial for PH-762.
• The company will seek additional funding to support its operations.
• The company will evaluate options to regain compliance with Nasdaq listing requirements.
• The company will meet with AgonOx to discuss the orderly wind-down of the Phase 1 clinical trial.

Key Dates

Keywords

Phio Pharmaceuticals, INTASYL, PH-762, immuno-oncology, clinical trial, biotechnology, cancer therapy, PD-1, RNA silencing, AgonOx